For this reason, dosing timing relative to meals and exercise can influence metabolic outcomes
The SURMOUNT-1 Phase 3 trial published in the New England Journal of Medicine demonstrated 20.9% mean body weight reduction at 72 weeks on tirzepatide 15mg weekly versus 3.1% with placebo
Make sure to choose such place for storage where there is no exposure to light and humidity
Front Endocrinol (Lausanne) 15:1432928
Gaussian 16, Revision C01, Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Petersson GA, Nakatsuji H, Li X, Caricato M, Marenich AV, Bloino J, Janesko BG, Gomperts R, Mennucci B, Hratchian HP, Ortiz JV, Izmaylov AF, Sonnenberg JL, Williams-Young D, Ding F, Lipparini F, Egidi F, Goings J, Peng B, Petrone A, Henderson T, Ranasinghe D, Zakrzewski VG, Gao J, Rega N, Zheng G, Liang W, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Throssell K, Montgomery JA, Peralta J, Ogliaro JE, Bearpark F, Heyd MJ, Brothers JJ, Kudin EN, Staroverov KN, Keith VN, Kobayashi TA, Normand R, Raghavachari J, Rendell K, Burant AP, Iyengar JC, Tomasi SS, Cossi J, Millam M, Klene JM, Adamo M, Cammi C, Ochterski R, Martin JWRL, Morokuma K, Farkas O